The combination of vinorelbine and trastuzumab was demonstrated to be highly effective in
several trials showing response rates in the range of 59-78%. This combination is
characterized by good tolerability and can be applied for a prolonged period without the
risk of major cumulative toxicity The availability of oral vinorelbine promises a further
simplification of therapy. The present trial therefore investigates the safety and efficacy
of a combined treatment with trastuzumab and oral vinorelbine.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate
Volker Heinemann, PhD, MD
Principal Investigator
University of Munich - Klinikum Grosshadern
Germany: Federal Institute for Drugs and Medical Devices
Mamma-2-2004
NCT00433095
Name | Location |
---|